Schwab Charles Investment Management Inc. grew its position in Agilent Technologies, Inc. (NYSE:A) by 1.4% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,332,267 shares of the medical research company’s stock after buying an additional 18,189 shares during the period. Schwab Charles Investment Management Inc. owned approximately 0.41% of Agilent Technologies worth $85,532,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in the company. BlackRock Inc. boosted its stake in Agilent Technologies by 1.2% in the 2nd quarter. BlackRock Inc. now owns 23,392,338 shares of the medical research company’s stock worth $1,387,400,000 after purchasing an additional 273,119 shares during the period. Vanguard Group Inc. boosted its stake in Agilent Technologies by 3.0% in the 2nd quarter. Vanguard Group Inc. now owns 22,093,669 shares of the medical research company’s stock worth $1,310,374,000 after purchasing an additional 637,698 shares during the period. JPMorgan Chase & Co. boosted its stake in Agilent Technologies by 45.2% in the 2nd quarter. JPMorgan Chase & Co. now owns 12,145,610 shares of the medical research company’s stock worth $720,358,000 after purchasing an additional 3,779,099 shares during the period. Bank of New York Mellon Corp boosted its stake in Agilent Technologies by 1.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 5,721,557 shares of the medical research company’s stock worth $339,346,000 after purchasing an additional 84,801 shares during the period. Finally, American Century Companies Inc. boosted its stake in Agilent Technologies by 5.5% in the 2nd quarter. American Century Companies Inc. now owns 4,582,086 shares of the medical research company’s stock worth $271,764,000 after purchasing an additional 238,522 shares during the period.

Shares of Agilent Technologies, Inc. (NYSE A) opened at $68.69 on Friday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 2.85 and a current ratio of 3.30. Agilent Technologies, Inc. has a 52-week low of $43.27 and a 52-week high of $70.93. The company has a market cap of $22,106.37, a PE ratio of 28.98, a price-to-earnings-growth ratio of 2.08 and a beta of 1.27.

Agilent Technologies (NYSE:A) last issued its quarterly earnings results on Monday, November 20th. The medical research company reported $0.67 EPS for the quarter, topping the consensus estimate of $0.62 by $0.05. Agilent Technologies had a net margin of 15.30% and a return on equity of 16.96%. The firm had revenue of $1.19 billion for the quarter, compared to analysts’ expectations of $1.17 billion. During the same period in the previous year, the firm posted $0.59 EPS. The company’s revenue for the quarter was up 7.0% on a year-over-year basis. sell-side analysts anticipate that Agilent Technologies, Inc. will post 2.58 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, January 24th. Shareholders of record on Tuesday, January 2nd will be given a dividend of $0.149 per share. The ex-dividend date of this dividend is Friday, December 29th. This is a boost from Agilent Technologies’s previous quarterly dividend of $0.13. This represents a $0.60 annualized dividend and a yield of 0.87%. Agilent Technologies’s payout ratio is 25.24%.

A number of equities analysts recently weighed in on A shares. Zacks Investment Research raised shares of Agilent Technologies from a “hold” rating to a “buy” rating and set a $76.00 target price for the company in a research note on Tuesday, October 31st. Robert W. Baird reaffirmed a “buy” rating and issued a $70.00 target price on shares of Agilent Technologies in a research note on Friday, October 20th. Cowen reaffirmed a “hold” rating and issued a $65.00 target price on shares of Agilent Technologies in a research note on Thursday, September 28th. Jefferies Group reaffirmed a “buy” rating and issued a $66.00 target price on shares of Agilent Technologies in a research note on Wednesday, August 9th. Finally, BidaskClub raised shares of Agilent Technologies from a “buy” rating to a “strong-buy” rating in a research note on Sunday, August 6th. Six investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. Agilent Technologies has an average rating of “Buy” and a consensus price target of $68.34.

In other news, CFO Didier Hirsch sold 1,200 shares of the company’s stock in a transaction dated Wednesday, September 13th. The shares were sold at an average price of $66.00, for a total value of $79,200.00. Following the sale, the chief financial officer now directly owns 164,202 shares of the company’s stock, valued at approximately $10,837,332. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Patrick Kaltenbach sold 5,000 shares of the company’s stock in a transaction dated Friday, September 8th. The shares were sold at an average price of $65.26, for a total transaction of $326,300.00. Following the completion of the sale, the insider now directly owns 45,143 shares in the company, valued at $2,946,032.18. The disclosure for this sale can be found here. Insiders have sold a total of 151,114 shares of company stock worth $10,359,388 over the last three months.

ILLEGAL ACTIVITY WARNING: “Agilent Technologies, Inc. (A) Shares Bought by Schwab Charles Investment Management Inc.” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/12/03/agilent-technologies-inc-a-shares-bought-by-schwab-charles-investment-management-inc.html.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.

Institutional Ownership by Quarter for Agilent Technologies (NYSE:A)

Receive News & Stock Ratings for Agilent Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies Inc. and related stocks with our FREE daily email newsletter.